KRAS and neoplasm: Likelihood of survival at 36 months was higher in patients with WT-KRAS tumours (35% vs. 14%; P < 0.001) (Figure 1), ECOG 0 patients (47% vs. 17%; P < 0.001), N0 patients (51% vs. 18%; P < 0.001), patients with tumours of classic adenocarcinoma histology (31% vs. 9%; P < 0.001).